these are fairly low risk trials - and this isn’t news. So minimizes the pop
The forehead and crows feet data are low risk, the rest aren't. The ph 2 CD data they have is pretty small numbers and noisy. In fact the GL data was lower risk and that doubled the stock when the ph 3 read out. If RVNC had truly derisked the therapeutic side with a differentiated product we wouldn't be here IMO. So I do in fact think the 2020 data readouts loom large
Market Data 
Markets 
AI
